Collegium Pharmaceutical, Inc. · NASDAQ:COLL
Collegium Pharmaceutical — FY2021 Earnings Presentation
17 slides from Collegium Pharmaceutical's earnings presentation, Feb 24, 2022
Slide 1: Q4 and FYE 2021 Earnings Report
February 24, 2022 | Nasdaq: COLL Q4 and FYE 2021 Earnings Report
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates,
Slide 3: Building a Leading, Diversified Specialty Pharmaceutical Company
A leader in responsible pain management Threecommercial-stage assets Strongfinancial positionDelivering value to our shareholders…and we are focused on buildingthe Collegium of tomorrowWe are proud of the Collegium we have built…3 Committed to improving the lives of people living with serious medica
Slide 4: 2022: A Pivotal Year for Collegium Pharmaceutical
CRITICALPRIORITIES•Renegotiate XER Contracts(accounting for ~50% of total prescriptions)•Manage Xtampza ER GtNto <65% (beginning in January 2023) 2022: A Pivotal Year for Collegium Pharmaceutical |XTAMPZAER CONTRACTRENEGOTIATIONSBUSINESSDEVELOPMENTACQUISITIONS•Diversify our portfolio through an accr
Slide 5: BDSI Rationale: Strategically and Financially Transformative
PORTFOLIO& FINANCIALDIVERSIFICATION•Doubles the number of commercial stage assets•Expands Collegium portfolio of differentiated pain solutions•Results in 2 durable growth drivers, 3 contributors to the top and bottom line, and a launch opportunity•Establishes a foothold in neurologyIMMEDIATESYNERGIE
Slide 6: 2021: Many Important Accomplishments
6Sources:1.IQVIA Monthly NPA through Dec 20212.Quarter-Ending Share3.Oxycodone extended-release market share2021: Many Important Accomplishments Filed prior approval supplement for Nucynta ER alternate manufacturingAnnounced opioid litigation settlement frameworkSupported communities through charita
Slide 7: 2021 Challenges
72021 Challenges COVID-19 DYNAMICS RETURNSADJUSTMENT
Slide 8: The Path Forward
The Path Forward A PERIODOFGROWTH& VALUECREATIONFinancially strong organization; Total revenue growth in 2022 driven by Xtampza ER; Stable contribution from the Nucynta Franchise A FOCUSEDORGANIZATIONCost structure aligned to our strategy and going forward ambitions; Strong cash flow generation; Sha
Slide 9: Financials
FinancialsColleen Tupper, Executive Vice President & Chief Financial Officer
Slide 10: FY21 Financial Highlights
1.This financial data was provided by Collegium Pharmaceutical, Inc., in its Form 10-K filed with the SEC February 24, 2022.2.Adjusted operating expenses exclude stock-based compensation, restructuring expenses, and litigation settlements.10FY21 Financial Highlights1,2 LEVERAGEDOPEX, FLATADJUSTEDOPE
Slide 11: Returns Adjustment
11Returns Adjustment SIGNIFICANTDISRUPTIONSINTHEPROCESSINGOFRETURNSREDUCEDREVENUEIN2021 GOINGFORWARDESTIMATED3.5% RETURNSRATE
Slide 12: 2022 Financial Guidance
121.Guidance excludes the impact from the proposed acquisition of BioDeliverySciences2.This financial data was provided by Collegium Pharmaceutical, Inc. in its Press Release filed with the SEC on February 24, 2022. TARGET1,2Total Revenues$315 million -$330 million2022 Financial Guidance Expect to i
Slide 13: Q&A
Q&A
Slide 14: 2022: A Pivotal Year for Collegium Pharmaceutical
CRITICALPRIORITIES•Renegotiate XER Contracts(accounting for ~50% of total prescriptions)•Manage Xtampza ER GtNto <65% (beginning in January 2023) 2022: A Pivotal Year for Collegium Pharmaceutical |XTAMPZAER CONTRACTRENEGOTIATIONSBUSINESSDEVELOPMENTACQUISITIONS•Diversify our portfolio through an accr
Slide 15: Non-GAAP Reconciliations
Non-GAAP Reconciliations NX
Slide 16: Reconciliation of GAAP Net Income to Adjusted EBITDA
16 Collegium Pharmaceutical, Inc.Reconciliation of GAAP Net Income to Adjusted EBITDA(in thousands)(unaudited) GAAP net (loss) income$ (25,034)$ 6,958 $ 71,517 $ 26,752 Adjustments: Interest expense 4,757 7,737 21,014 28,882 Interest income(3) (3) (12) (232) Provision for (benefit from) income taxes
Slide 17: Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses
17 20212020 20212020 GAAP Operating expenses$ 32,789 29,296 132,989 123,604 Adjustments: Stock-based compensation 4,912 6,210 24,255 21,910 Restructuring 4,578 - 4,578 - Litigation settlements 2,935 - 2,935 - Total adjustments 12,425 6,210 31,768 21,910 Adjusted operating expenses$ 20,364 $ 23,086 $
Collegium Pharmaceutical — FY2021 Earnings Presentation on 6ix